Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy

Sung-Eun LeeDepartment of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea;

Soo-Young ChoiLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Soo-Hyun KimLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Hye-Young SongLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Hae-Lyun YooLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Mi-Young LeeLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Hee-Jeong HwangLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Ki-Hoon KangLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Kyung-Mi KeeLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Eun-Jung JangLeukemia Research Institute, The Catholic University of Korea, Seoul, Korea

Dong-Wook KimDepartment of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea; ;Leukemia Research Institute, The Catholic University of Korea, Seoul, KoreaCorrespondence[email protected]

show all

Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary Figure 2

Supplementary Figure 1

Supplementary Table I and Supplementary Figure Legends

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary Figure 2

Supplementary Figure 1

Supplementary Table I and Supplementary Figure Legends

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date